ReviewArchives of academic emergency medicine2020
Management of Pemphigus in COVID-19 Pandemic Era; a Review Article.
Review in Archives of academic emergency medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 19 citations in OpenAlex.
- Outcomes and risk factors of COVID-19 in patients with bullous pemphigoid: a cross-sectional study.Frontiers in immunology · 2025Article
- Pemphigus during the COVID-19 Epidemic: Infection Risk, Vaccine Responses and Management Strategies.Journal of clinical medicine · 2022Review
- Multisystem Inflammatory Syndrome and Autoimmune Diseases Following COVID-19: Molecular Mechanisms and Therapeutic Opportunities.Frontiers in molecular biosciences · 2022Review
- Which immunosuppressive drug is preferred in the treatment of toxic epidermal necrolysis during COVID-19 outbreak?Clinical case reports · 2021Article
- Skin manifestations of COVID-19 in children: Part 3.Clinical and experimental dermatology · 2021Review
- Can rituximab be used in the treatment of pemphigus vulgaris during the COVID-19 pandemic?Dermatologic therapy · 2021Article
- Rituximab as the treatment of pemphigus vulgaris in the COVID-19 pandemic era: A narrative review.Dermatologic therapy · 2021Review
- Treatment concerns for bullous pemphigoid in the COVID-19 pandemic era.Dermatologic therapy · 2020Review
- Aggressive course of pemphigus vulgaris following COVID-19 infection.Dermatologic therapy · 2020Article
- Impact of COVID-19 on autoimmune blistering diseases.Clinics in dermatologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The novel coronavirus is rapidly spreading around the world. Since the public announcement of the COVID-19 outbreak, several concerns have been raised by dermatologists as well as pemphigus patients who take immunosuppressive drugs. In this paper, we review the literature about the common treatment of pemphigus with a focus on the lessons from similar epidemics to find a proper suggestion to manage pemphigus in the COVID-19 pandemic era. The effect of many of the drugs used for treatment of Pemphigus vulgaris (PV) on COVID-19 is not clear. We also do not have data on the impact of this autoimmune disease, which may involve the mucous membranes, on the acquisition or course of COVID-19. We are currently in the midst of a pandemic and evaluating the effect of COVID-19 on the population of susceptible patients suffering from auto-immune diseases like pemphigus is essential. The evidence on best ways to manage patients with underlying conditions, such as pemphigus, during the outbreak of COVID-19 is evolving and the data is updated every day.
Indexed as
Identifiers
32440662PMC7212074W3022434981What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.